$95.62
7.06% today
Nasdaq, Apr 04, 09:17 pm CET
ISIN
US64125C1099
Symbol
NBIX

Neurocrine Biosciences, Inc. Stock price

$102.88
-11.60 10.13% 1M
-9.00 8.04% 6M
-33.62 24.63% YTD
-34.71 25.23% 1Y
+5.38 5.52% 3Y
+17.10 19.93% 5Y
+63.36 160.32% 10Y
Nasdaq, Closing price Thu, Apr 03 2025
-5.43 5.01%
ISIN
US64125C1099
Symbol
NBIX
Sector
Industry

Key metrics

Market capitalization $10.26b
Enterprise Value $9.68b
P/E (TTM) P/E ratio 31.26
EV/FCF (TTM) EV/FCF 17.37
EV/Sales (TTM) EV/Sales 4.11
P/S ratio (TTM) P/S ratio 4.36
P/B ratio (TTM) P/B ratio 3.95
Revenue growth (TTM) Revenue growth 24.81%
Revenue (TTM) Revenue $2.36b
EBIT (operating result TTM) EBIT $583.00m
Free Cash Flow (TTM) Free Cash Flow $557.20m
Cash position $1.08b
EPS (TTM) EPS $3.29
P/E forward 24.98
P/S forward 3.84
EV/Sales forward 3.62
Short interest 3.87%
Show more

Is Neurocrine Biosciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Neurocrine Biosciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

28 Analysts have issued a Neurocrine Biosciences, Inc. forecast:

22x Buy
79%
6x Hold
21%

Analyst Opinions

28 Analysts have issued a Neurocrine Biosciences, Inc. forecast:

Buy
79%
Hold
21%

Financial data from Neurocrine Biosciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
2,355 2,355
25% 25%
100%
- Direct Costs 58 58
0% 0%
2%
2,298 2,298
26% 26%
98%
- Selling and Administrative Expenses 980 980
13% 13%
42%
- Research and Development Expense 708 708
29% 29%
30%
610 610
47% 47%
26%
- Depreciation and Amortization 27 27
27% 27%
1%
EBIT (Operating Income) EBIT 583 583
48% 48%
25%
Net Profit 341 341
37% 37%
14%

In millions USD.

Don't miss a Thing! We will send you all news about Neurocrine Biosciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Neurocrine Biosciences, Inc. Stock News

Neutral
Investors Business Daily
about 4 hours ago
The top five biotech stocks today have several commonalities. Among them are strong ratings.
Neutral
PRNewsWire
about 8 hours ago
Accomplished physician-scientist brings more than 20 years of industry leadership experience and broad R&D expertise in multiple therapeutic areas  SAN DIEGO , April 4, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the appointment of Sanjay Keswani, M.D., to the company's executive management team as Chief Medical Officer (CMO) effective June 2, 2025.
Neutral
PRNewsWire
4 days ago
All Patients Treated with INGREZZA® (valbenazine) Capsules Reached a Therapeutic Dose from Day One, While Only Approximately Half of Patients Treated with Deutetrabenazine Were Able to Reach a Therapeutic Dose Within Six Months Findings Presented at the Academy of Managed Care Pharmacy 2025 Annual Meeting SAN DIEGO , March 31, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) tod...
More Neurocrine Biosciences, Inc. News

Company Profile

Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The company product includes INGREZZA. Neurocrine Biosciences was founded by Kevin C. Gorman and Wylie W. Vale on January 1992 and is headquartered in San Diego, CA.

Head office United States
CEO Kyle Gano
Employees 1,800
Founded 1992
Website www.neurocrine.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today